血管內(nèi)皮生長(zhǎng)因子C(VEGFC)真核蛋白
Eukaryotic Vascular Endothelial Growth Factor C (VEGFC)
VEGF-C; Flt4-L; VRPL; Vascular Endothelial Growth Factor-Related Protein
- 編號(hào)EPA145Rb62
- 物種Oryctolagus cuniculus (Rabbit，兔) 相同的名稱，不同的物種。
- 來(lái)源真核表達(dá)
- 宿主293F cell
- 內(nèi)毒素水平<1.0EU/µg(LAL法測(cè)定)
- 亞細(xì)胞定位分泌
- 預(yù)測(cè)分子量14.7kDa
- 實(shí)際分子量22kDa(差異分析請(qǐng)參閱說(shuō)明書)
- 片段與標(biāo)簽Ala111~Arg226 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)8.5
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請(qǐng)參見活性蛋白。 - 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1044 ¥ 2610 ¥ 5220 ¥ 15660 ¥ 39150
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. SDS-PAGE
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月，-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Oryctolagus cuniculus (Rabbit，兔) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA145Rb01 | 血管內(nèi)皮生長(zhǎng)因子C(VEGFC)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPA145Rb61 | 血管內(nèi)皮生長(zhǎng)因子C(VEGFC)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPA145Rb62 | 血管內(nèi)皮生長(zhǎng)因子C(VEGFC)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA145Rb61 | 血管內(nèi)皮生長(zhǎng)因子C(VEGFC)活性蛋白 | Cell?culture;?Activity?Assays. |
| PAA145Rb01 | 血管內(nèi)皮生長(zhǎng)因子C(VEGFC)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA145Rb51 | 血管內(nèi)皮生長(zhǎng)因子C(VEGFC)多克隆抗體 | WB; IHC; ICC; IP. |
| SEA145Rb | 血管內(nèi)皮生長(zhǎng)因子C(VEGFC)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Journal of Cellular Biochemistry | Alternatively activated RAW264. 7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma [PubMed: 19241443] |
| genetics and molecular research | Expression of COX-2 and VEGF-C in cholangiocarcinomas at different clinical and pathological stages [PubMed: 26125824] |
| Experimental and Therapeutic | Fenofibrate inhibits the expression of VEGFC and VEGFR-3 in retinal pigmental epithelial cells exposed to hypoxia [PubMed: 26622498] |
| Am J Pathol | IL-10 Indirectly Regulates Corneal Lymphangiogenesis and Resolution of Inflammation via Macrophages [PubMed: 26608451] |
| PLoS One. | Interleukin-6 Induces Vascular Endothelial Growth Factor-C Expression via Src-FAK-STAT3 Signaling in Lymphatic Endothelial Cells. [pubmed:27383632] |
| Oncology?Letters | RNAi-mediated?gene?silencing?of?vascular?endothelial?growth?factor?C?suppresses?growth?andinduces?apoptosis?in?mouse?breast?cancer?in?vitro?and in?vivo. [pubmed:27895746] |
| Angiogenesis | Characterization of isolated liver sinusoidal endothelial cells for liver bioengineering [Pubmed:29582235] |
| Oncology Reports | Effects of diphyllin as a novel V-ATPase inhibitor on TE-1 and ECA-109 cells [Pubmed:29328465] |
| LABORATORY INVESTIGATION | Dynamic signature of lymphangiogenesis during acute kidney injury and chronic kidney disease [Pubmed: 31019289] |
| Cutaneous and Ocular Toxicology | Isotretinoin does not alter VEGF-A and VEGF-C levels: Do retinoids behave differently in dose-dependent and/or in vivo/in vitro conditions? [Pubmed: 32722957] |
留言咨詢
